Cargando…
Evaluation of the prophylaxis and treatment of COVID-associated coagulopathy
Most of the current “literature” surrounding the presence of thrombosis in COVID-19 disease and appropriate prophylaxis/treatment modalities is certainly retrospective at best, and anecdotal at worst. But in these times of rapidly changing information and perspective, an assessment of all available...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586671/ https://www.ncbi.nlm.nih.gov/pubmed/33117545 http://dx.doi.org/10.1186/s40545-020-00274-8 |
_version_ | 1783600046794604544 |
---|---|
author | Elbeddini, Ali Gerochi, Rachel Elshahawi, Ahmed |
author_facet | Elbeddini, Ali Gerochi, Rachel Elshahawi, Ahmed |
author_sort | Elbeddini, Ali |
collection | PubMed |
description | Most of the current “literature” surrounding the presence of thrombosis in COVID-19 disease and appropriate prophylaxis/treatment modalities is certainly retrospective at best, and anecdotal at worst. But in these times of rapidly changing information and perspective, an assessment of all available data (including expert opinion) is the goal of this review. Bleeding risk factors for COVID-19-associated bleeding may include other systemic diseases, including hypertension, diabetes, cardiovascular disease, and immunosuppression. Individuals with hypertension should not discontinue their medication. Current evidence does not support changes in the management of hypertension. As COVID-19 progresses, coagulation pathways are activated as part of the host inflammatory response to limit the viral infection. Specifically, D-dimers, products of fibrin as it is degraded within clots, are elevated in many cases of hospitalized COVID-19 patients. D-dimers are an indicator of a clot (thrombus) formation and breakdown. More severe COVID-19 disease may lead to overt disseminated intravascular coagulation (DIC), associated with high mortality. DIC is a coagulopathy that may arise from the systemic inflammatory response to the virus and damaged tissue caused by the infection. Bleeding risk factors may include other systemic diseases, including hypertension, diabetes, cardiovascular disease, and immunosuppression. Individuals with hypertension should not discontinue their medication. Current evidence does not support changes in the management of hypertension. As COVID-19 progresses, coagulation pathways are activated as part of the host inflammatory response to limit the viral infection. Specifically, D-dimers, products of fibrin as it is degraded within clots, are elevated in many cases of hospitalized COVID-19 patients. D-dimers are an indicator of a clot (thrombus) formation and breakdown. More severe COVID-19 disease may lead to overt disseminated intravascular coagulation (DIC), associated with high mortality. DIC is a coagulopathy that may arise from the systemic inflammatory response to the virus and damaged tissue caused by the infection. My manuscript presents the risk and evidence around the COVID-19-associated coagulopathies |
format | Online Article Text |
id | pubmed-7586671 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-75866712020-10-27 Evaluation of the prophylaxis and treatment of COVID-associated coagulopathy Elbeddini, Ali Gerochi, Rachel Elshahawi, Ahmed J Pharm Policy Pract Commentary Most of the current “literature” surrounding the presence of thrombosis in COVID-19 disease and appropriate prophylaxis/treatment modalities is certainly retrospective at best, and anecdotal at worst. But in these times of rapidly changing information and perspective, an assessment of all available data (including expert opinion) is the goal of this review. Bleeding risk factors for COVID-19-associated bleeding may include other systemic diseases, including hypertension, diabetes, cardiovascular disease, and immunosuppression. Individuals with hypertension should not discontinue their medication. Current evidence does not support changes in the management of hypertension. As COVID-19 progresses, coagulation pathways are activated as part of the host inflammatory response to limit the viral infection. Specifically, D-dimers, products of fibrin as it is degraded within clots, are elevated in many cases of hospitalized COVID-19 patients. D-dimers are an indicator of a clot (thrombus) formation and breakdown. More severe COVID-19 disease may lead to overt disseminated intravascular coagulation (DIC), associated with high mortality. DIC is a coagulopathy that may arise from the systemic inflammatory response to the virus and damaged tissue caused by the infection. Bleeding risk factors may include other systemic diseases, including hypertension, diabetes, cardiovascular disease, and immunosuppression. Individuals with hypertension should not discontinue their medication. Current evidence does not support changes in the management of hypertension. As COVID-19 progresses, coagulation pathways are activated as part of the host inflammatory response to limit the viral infection. Specifically, D-dimers, products of fibrin as it is degraded within clots, are elevated in many cases of hospitalized COVID-19 patients. D-dimers are an indicator of a clot (thrombus) formation and breakdown. More severe COVID-19 disease may lead to overt disseminated intravascular coagulation (DIC), associated with high mortality. DIC is a coagulopathy that may arise from the systemic inflammatory response to the virus and damaged tissue caused by the infection. My manuscript presents the risk and evidence around the COVID-19-associated coagulopathies BioMed Central 2020-10-26 /pmc/articles/PMC7586671/ /pubmed/33117545 http://dx.doi.org/10.1186/s40545-020-00274-8 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Commentary Elbeddini, Ali Gerochi, Rachel Elshahawi, Ahmed Evaluation of the prophylaxis and treatment of COVID-associated coagulopathy |
title | Evaluation of the prophylaxis and treatment of COVID-associated coagulopathy |
title_full | Evaluation of the prophylaxis and treatment of COVID-associated coagulopathy |
title_fullStr | Evaluation of the prophylaxis and treatment of COVID-associated coagulopathy |
title_full_unstemmed | Evaluation of the prophylaxis and treatment of COVID-associated coagulopathy |
title_short | Evaluation of the prophylaxis and treatment of COVID-associated coagulopathy |
title_sort | evaluation of the prophylaxis and treatment of covid-associated coagulopathy |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586671/ https://www.ncbi.nlm.nih.gov/pubmed/33117545 http://dx.doi.org/10.1186/s40545-020-00274-8 |
work_keys_str_mv | AT elbeddiniali evaluationoftheprophylaxisandtreatmentofcovidassociatedcoagulopathy AT gerochirachel evaluationoftheprophylaxisandtreatmentofcovidassociatedcoagulopathy AT elshahawiahmed evaluationoftheprophylaxisandtreatmentofcovidassociatedcoagulopathy |